Background. The interval between neoadjuvant chemoradiation treatment and surgery has been described as an important predictor of pathologic response to therapy in nonesophageal cancer sites. We retrospectively reviewed our experience with patients who underwent neoadjuvant chemoradiation and esophagectomy to better understand the impact of the timing of surgery on pathologic complete response rates in esophageal cancer.
Methods. Two hundred thirty-one sequentially treated patients from 2000 to 2011 were identified for this study; 88 of these patients completed neoadjuvant chemoradiation followed by esophagectomy at our institution. The interval between completion of chemoradiation and surgery was calculated for each patient. The patients were categorized into quartiles and also into 3-week interval groups. Treatment factors and surgical morbidity data, including the estimated blood loss and length of operative stay, were also assessed.
Results. Quartiles for the neoadjuvant chemoradiation to surgery interval were less than 45 days, 46 to 50 days, 51 to 63 days, and 64D days. Corresponding pathologic complete response rates were 12.5%, 20.0%, 22.7%, and 40.9% (p [ 0.03). Results for 3-week intervals were similar (p [ 0.02). There was no association between increasing time interval between the ending of neoadjuvant chemoradiation to surgery and length of stay longer than 2 weeks.
Conclusions. A longer interval between completion of neoadjuvant chemoradiation and surgery was associated with higher pathologic complete response rates without an impact on surgical morbidity.
(Ann Thorac Surg 2015;99:270-6) Ó 2015 by The Society of Thoracic Surgeons E sophageal cancer is an aggressive malignancy that is associated with high mortality rates. Five-year survival for all stages is 17%, and even patients with localized disease have a survival rate of only 37%. Trimodality treatment with preoperative chemoradiotherapy has been shown to improve survival rates versus surgery alone and is accepted as a standard of care for esophageal cancer patients [1] [2] [3] [4] [5] . Neoadjuvant chemoradiation treatment (NCRT) has been shown to decrease locoregional failure control (14.1% with NCRT versus 33.5% with surgery alone at 45 months) as well as distant failure rates (31.5% versus 47.8%, respectively), thereby improving outcomes [6] . Studies have demonstrated that pathologic complete response (pCR) in patients undergoing trimodality treatment for esophageal cancer predicts decreased local and distant recurrence, as well as improved survival [7] [8] [9] .
Because of the potential implications of pCR in patients with esophageal cancer, identifying variables effecting pCR is important. The interval between neoadjuvant treatment and surgery has been implicated as an important factor in other disease sites, such as rectal adenocarcinoma, in predicting pathologic response to therapy. In squamous cell carcinoma of the anal canal, tumor regression after chemoradiation can be seen as long as 6 months after completion of therapy. Increasing this interval after completion of preoperative therapy may allow the tumor to continue to regress, thereby improving resectability, or allow a more accurate assessment of the maximal effect of NCRT. However, theoretically, waiting too long for regression may allow for tumor repopulation or increased radiation fibrosis, adding to the complexity and complications of surgery. We retrospectively reviewed our experience with patients who underwent esophagectomy to better understand the impact of the interval between the end of NCRT therapy and surgery on pCR rates in esophageal cancer.
Material and Methods
After Institutional Review Board approval, all patients who underwent NCRT for esophageal cancer at Fox Chase Cancer Center between September 2000 and September 2011 were retrospectively reviewed. Clinical records identified 231 patients with esophageal cancer undergoing chemoradiation, of whom 91 underwent subsequent surgery. The records of 2 patients who underwent radiation treatment at another facility were not available at the time of analysis, and another patient did not complete radiation treatment. Thus, 88 patients were included in this study. For the evaluation of postsurgical outcomes, 3 patients were excluded because of surgery at an outside institution, and 1 patient was excluded because he underwent a total gastrectomy, not an esophagectomy.
All patients were staged preoperatively and postoperatively according to the tumor-node-metastasis classification of the American Joint Committee for Cancer Staging, Seventh Edition [10] . Pretreatment clinical staging routinely included computed tomography scan, esophagogastroduodenoscopy and biopsy, bronchoscopy, endoscopic ultrasonography, and positron emission tomography scan. Patients with no viable tumor cells in the surgical specimen (ypT0N0M0) were classified as having a pCR; all other patients were considered to have either gross residual or microscopic disease.
Baseline data collected included general patient characteristics (age, sex, diagnosis date, histology), treatment characteristics (chemotherapy regimen, radiation dose, type of surgery), toxicity, and tumor recurrence. Followup data were obtained from patient medical records, referring physicians, and telephone interviews.
We determined the NCRT-to-surgery interval from the last day of radiation treatment to the day of surgery. This variable was examined as both a continuous and categorical predictor. Owing to the skewed distribution (Fig 1) , we also considered the log-transformed interval. As a categorical variable, we evenly classified patients according to interval quartiles and 3-week groups (3 to 6 weeks, 6 to 9 weeks, 9 to 12 weeks, and >12 weeks). Both interval quartiles and 3-week groups were created to divide patients evenly by number (interval quartiles) and by regular periods (3-week groups). The primary outcome was pCR (yes versus no). We evaluated the association of quartiles and 3-week groups with the binary outcome of pCR using the Cochran-Armitage trend test. We used the odds ratio from univariate logistic regression to measure the association of the interval (as a continuous variable, log transformed variable, or categorical variable) with pCR. We also used logistic regression to evaluate potential confounders including age, sex, T stage, N stage, histology, type of chemotherapy, and type of radiation. Statistically significant confounders would have been included as covariates in multivariable logistic regression to assess the impact on the association with the NCRT to surgery interval; however, none of the confounders was significantly related to the outcome. Overall survival was estimated using the Kaplan-Meier method. The Cox proportional hazards model was used adjusting for age.
Estimated blood loss (EBL) was considered as both a continuous and categorical variable (approximately 100-mL intervals). Spearman's rank correlation (nonparametric) was used to estimate the association between EBL and the interval as continuous variables. Linear regression was used to assess the trend between EBL as a categorical variable and the post-NCRT to surgery interval. Length of hospital (LOS) stay of more than 2 weeks (yes/no) was evaluated similar to the pCR outcome, using the Cochran-Armitage trend test, and odds ratios from univariate logistic regression, and multivariable analysis to adjust for significant univariate confounders. Statistical significance was determined using a 5% type I error. All analyses were conducted using SAS statistical software (version 9.3; SAS Institute, Cary, NC).
Results
Of the patients completing trimodality therapy, 75 were men and 13 were women; the median age was 61 years (range, 36 to 80). The cancer was adenocarcinoma in 74 patients (84.1%) and squamous cell carcinoma in 14 patients (15.9%). Eight patients (9.1%) had T1/T2 lesions, and 80 patients (88.9%) had T3/T4 lesions. The median follow-up of the cohort was 87.7 months. Clinical characteristics of these patients can be found in Table 1 .
The induction regimen varied, with the median radiation dose being 50.4 Gy (range, 45 to 60 Gy). Sixteen patients (18.1%) received intensity-modulated radiation therapy (IMRT), and 72 (81.8%) underwent three-dimensional conformal radiotherapy. Seventy-one patients (80.7%) received 5-fluorouracil-based therapy, and 17 patients (19.3%) received paclitaxel (Taxol)-based therapy.
Surgical treatment was guided by the location of the tumor as well as by surgeon preference. Eighteen patients underwent three-hole minimally invasive esophagectomy, 68 patients underwent Ivor-Lewis esophagectomy, 1 patient underwent a transhiatal esophagectomy, and 1 patient underwent total gastrectomy. Twenty-one patients (23.9%) had a pCR after NCRT, and 67 patients (76.1%) had residual or microscopic disease on pathology of the primary tumor or lymph nodes. The majority of patients with residual or microscopic disease had it in the lymph nodes and esophagus (47.8%) or in the esophagus alone (44.8%).
The median number of days between completion of NCRT and surgery was 50.5 (range, 26 to 204 days). The Values are number of patients (%), unless otherwise specified.
5-FU ¼ 5-fluorouracil;
IMRT ¼ intensity modulated radiotherapy; RT ¼ radiotherapy; SCC ¼ squamous cell carcinoma; 3D-CRT ¼ threedimensional conformal radiotherapy. median time from completion of NCRT to surgery was 57 days for patients achieving pCR and 50 days for patients with residual or microscopic disease on pathology. When divided evenly by number of patients, quartiles for the NCRT to surgery interval were less than 45 days, 46 to 50 days, 51 to 63 days, and 64þ days (Fig 2A) . There were no significant differences in terms of patient characteristics between the groups aside from histology (p ¼ 0.04; Table 1 ). The pCR was 12.5%, 20.0%, 22.7%, and 40.9% for each of these quartiles, respectively (p ¼ 0.03; Table 2 ). Among patients who had an interval longer than 64 days, 8 patients (36.4%) had a longer interval due to post-NCRT hospitalization and another 8 (36.4%) had a poor performance status after NCRT. Other reasons for a delayed interval included patient decision (3 patients), scheduling difficulties (2 patients), and perioperative clearance problems (1 patient). The NCRT to surgery intervals were also categorized into 3-week groups, namely, 3 to 6 weeks, 6 to 9 weeks, 9 to 12 weeks, and 12þ weeks (Fig 2B) . The pCR rate was 11.8% (2 of 17) in the shortest interval and 50.0% (3 of 6) in the longest interval group, with a significant difference across the four groups (p ¼ 0.02). Univariable logistic regression also showed a difference in pCR rates when the interval between NCRT and surgery was examined as a continuous variable (odds ratio for pCR for a difference of 1 week ¼ 1.20, 95% confidence interval: 1.01 to 1.42, p ¼ 0.04) and a log transformed continuous variable (p ¼ 0.02; Table 3 ).
Analysis of tumor characteristics including tumor stage, node positivity, and histology revealed no significant difference in tumor response (Table 3) . Furthermore, when stratifying patients according to chemotherapy regimen or radiation dose, there was no difference in tumor response to treatment. Patient characteristics such as sex or age also did not affect the response of the tumor after trimodality treatment. Because none of these characteristics was significantly related to pCR, they were not considered potential confounders of the interval and pCR association, and therefore were not added as covariates to the model for interval and pCR.
Patients achieving pCR had an improved overall survival versus patients with residual or microscopic disease (p ¼ 0.05). When analyzing by interval between NCRT to surgery, there was no difference in overall survival by interval quartile (p ¼ 0.30) or by 3-week interval group (p ¼ 0.13; Fig 3) . In a Cox model adjusting for age, the interval quartile (p ¼ 0.24) and 3-week quartile group (p ¼ 0.17) still did not reach statistical significance.
Of the 85 patients for whom surgical data were available, the median LOS was 12 days (range, 8 to 35). Of these patients, 23 (27.1%) had LOS longer than 14 days. There was no significant trend between LOS longer than 14 days and either interval quartile (p ¼ 0.17) or 3-week interval group (p ¼ 0.60). The median amount of EBL was 200 cc (range, 50 to 800 cc). No significant relationship between time interval and EBL was found (p ¼ 0.54).
Comment
Despite improvements in technology and treatment modalities, the prognosis for esophageal cancer patients remains poor, with 5-year survival rates ranging from 17% to 37%. The cornerstone of managing these patients remains esophagectomy, although the addition of NCRT has become the standard of care in many institutions throughout the country. The ideal interval between NCRT and surgery is not well defined. The typical goal of 4 to 6 weeks is somewhat arbitrary, with the intent of allowing resolution of acute inflammation as well as allowing for tumor regression while minimizing the chronic fibrotic changes in the surgical field. In theory, that may both improve resectability and decrease morbidity after esophagectomy.
A study by Berger and associates [8] retrospectively reviewed 171 patients who received an esophagectomy either with or without NCRT. Patients who achieved pCR after trimodality treatment showed a median overall survival of 50 months and a 5-year survival rate of 48% versus a median survival of 25 months and 5-year survival of 15% for patients without neoadjuvant therapy. The value of pCR has also been shown in a prospectively collected dataset by Stahl [9] , who demonstrated that each of the 8 patients who achieved pCR with neoadjuvant therapy was alive and disease free at last follow-up.
Numerous studies have demonstrated that patients with pCR after NCRT therapy have improved survival outcomes. Kleinberg and associates [11] reviewed 92 patients with esophageal cancer who underwent NCRT followed by esophagectomy. At a median follow-up of 63.5 months, a total of 30 patients (33%) achieved pCR.
Patients achieving pCR had a survival rate of 67%, compared with 27% for patients without pCR. Other studies have demonstrated similar response rates after neoadjuvant treatment [2-5, 12, 13] . Our findings were consistent with the literature as patients achieving a pCR had an improved overall survival compared with patients who had residual or microscopic disease. Although patients with a longer interval between NCRT and surgery had a higher rate of pCR, that did not translate into an improvement in overall survival. Reasons for this disconnect may be small sample sizes in each cohort. For rectal cancer, the Lyon R90-01 trial examined the outcomes of patients after preoperative radiation treatment [14] . Interestingly, patients with a long interval (6 to 8 weeks) between radiation and surgery versus a short interval (within 2 weeks) were found to have a better clinical response and pathologic downstaging, although both groups had similar local control and overall survival. Other studies in rectal cancer have demonstrated similar findings [15, 16] . That brings into question whether time elapsed between neoadjuvant treatment and surgery alters patient outcomes at other disease sites.
Our study examined tumor regression rates by evaluating the number of patients who had pCR or residual disease after NCRT. When stratifying patients according to time elapsed between completion of NCRT and surgery, there was an increased pCR rate among patients with more time elapsed between NCRT and surgery. Unlike the Lyon R0-01 study, our cohort of patients also received neoadjuvant chemotherapy, yet the outcome was similar. Patients with a longer interval to surgery appeared to have better downstaging and response rates.
Tessier and associates [17] recently examined the optimal timing of surgery for patients undergoing neoadjuvant chemoradiation for esophageal cancer. In their cohort of 257 patients, they found no association between delay in surgical intervention and outcomes [17] . A study by Kim and associates [18] examined 266 patients who underwent trimodality therapy to determine whether increased interval between NCRT and surgery was associated with perioperative complications, pathologic response, and overall survival. In their dataset, there was no correlation between time and the above outcomes [18] . A study by Rizk and associates [19] examined 276 patients undergoing trimodality treatment for esophageal cancer. With a median time from completion of radiation to surgery of 49 days, they reported no difference in patient outcomes based on the interval from radiation completion and surgery. Similarly, Koshy and colleagues [20] found that with a median lapse of 7 weeks between treatments, there was no significant effect on tumor response.
Although other studies have demonstrated no significant impact of the time between NCRT and surgery, our data suggest a possible advantage of delayed resection. This disparity may occur for various reasons. Prior studies have had a much shorter median interval between NCRT and surgery, thus possibly preventing any significant difference in response to be assessed. Also, prior retrospective studies have examined different chemotherapy regimens and a mix of histologies weighted more toward squamous cell carcinomas [5] . These factors may impact the velocity of treatment response. Inherent biases may also impact the different outcomes in these studies. Although our study groups do not appear to have any differences in terms of treatment-related factors, other disparities between the groups may be unaccounted for. Finally, statistical methods between these studies vary. In our analysis, we examine differences in these cohorts using the endpoint as both a continuous and categorical predictor. Other analyses have used timing as a dichotomous variable, which may not account for the varied distribution as evident in our analysis.
In our patient analysis, longer intervals were associated with increased LOS. That is not surprising, as gaps between completion of NCRT and surgery are often because of the toxicity of initial therapy. Although patients completing NCRT are typically presumed to have worse perioperative outcomes, a recent study demonstrated that patients who completed NCRT followed by esophagectomy were more likely to have a reduced LOS compared with patients who only underwent surgery [21] .
As with any retrospective analysis, the main limitation of this study is the nonrandomization of patients allocated to each group. Owing to the nature of NCRT, patients may have significant morbidity, which makes surgeons more apt to suggest additional recovery time before surgery. Surgery may also be delayed owing to suspicion of distant metastasis during NCRT; therefore, patients with delays who do not have evidence of distant disease may have been biologically selected as responders to therapy. However, prospective randomized trials have strict timeframes for protocol treatment, and by their nature would limit an analysis of the type we have performed. In addition, not all patients undergoing chemoradiation undergo surgical resection. In our cohort, of 231 patients undergoing chemoradiation, only 91 patients underwent surgical resection and 88 could be evaluated.
In summary, this study suggests that, similar to findings at other disease sites, patients with esophageal cancer may have better response rates with longer interval between chemoradiotherapy and surgery. To our knowledge, this is the first study reporting such a finding in esophageal cancer patients receiving NCRT. When examining pCR as a surrogate endpoint, it may be important to keep the interval from NCRT to surgery in mind, as early surgery may underestimate the efficacy of chemoradiation. Importantly, although longer time to surgery improved response rates, it did not significantly affect overall surgical morbidity as measured by LOS and EBL. This study emphasizes the importance of future studies to gain a better understanding of the ideal interval between NCRT and surgery for esophageal cancer patients.
